This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre Hospitalier Régional Universitaire De Tours, National Institute of Health and Medical Research, Universite De Tours. Active years: 2014-2020.
Company Filing History:
1 out of 5 
1 out of 1,853 
1 out of 19 Years Active: 2014-2020
Title: **Christophe Hourioux: Innovator in Vaccine Development**
Introduction
Christophe Hourioux, an accomplished inventor based in Druye, France, has made significant strides in the field of vaccine development. With a total of two patents to his name, Hourioux's work focuses on creating innovative fusion proteins for the preparation of vaccines against various viral hepatitis infections.
Latest Patents
Hourioux's recent patents include groundbreaking immunogenic fusion proteins that incorporate peptides from viruses. His first patent describes a fusion protein designed for preparing vaccines that include a sequence from the human hepatitis B virus (HBV) protein S or M, along with specific elements from the Zika virus. These fusion proteins represent a novel approach in the creation of effective vaccines.
The second patent focuses on the development of a fusion protein for hepatitis C vaccines. This invention features a combination of the hepatitis B virus S protein and the envelope proteins of the hepatitis C virus (HCV). A key aspect of this patent is the description of a hybrid nucleic acid molecule that encodes the fusion protein, complete with a cell line for its production, showcasing Hourioux's innovative methodologies in the biotechnology domain.
Career Highlights
Christophe Hourioux has had an impressive career, notably working at reputable institutions such as Université François-Rabelais de Tours and Université de Tours. His contributions to the academic and research community have significantly influenced the development of advanced medical technologies.
Collaborations
Throughout his career, Hourioux has collaborated with esteemed colleagues, including Philippe Roingeard and Romuald Patient. These partnerships have allowed him to leverage diverse expertise and insights in advancing research initiatives aimed at combating viral diseases.
Conclusion
Christophe Hourioux stands out as a remarkable inventor in the field of vaccine research and development. His innovative patents reflect a commitment to improving health outcomes and demonstrate the potential for fusion proteins to play a critical role in vaccine formulation. With ongoing research and collaboration, Hourioux is likely to further impact the landscape of vaccine technology.